Aurinia Pharmaceuticals Inc
Gesloten
SectorGezondheidszorg
18.63 3.9
Overzicht
Wijziging aandelenprijs
24u
Min
17.8
Max
19.19
Inkomsten | -176M 34M |
|---|---|
Verkoop | 591K 78M |
K/W Sectorgemiddelde | 8.051 50.958 |
EPS | 0.25 |
Winstmarge | 44.212 |
Werknemers | 128 |
EBITDA | 2.7M 50M |
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | -12.36% downside |
Volgende Winsten | 30 jul 2026 |
|---|
Marktkapitalisatie | 187M 2.2B |
|---|---|
Vorige openingsprijs | 14.73 |
Vorige sluitingsprijs | 18.63 |
Nieuwssentiment
By Acuity
50%
50%
146 / 342 Rangschikking in Healthcare
Aurinia Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
